Does the emergence of antibiotic resistance announce the return of the dark ages?;L'́mergence de la ŕsistance aux antibiotiques annonce-t-elle le retour des âges sombres ?

Annales de Biologie Clinique

Volumn 69, Issue 6, 2011, Pages 637-646

  Elhani, Dalèle ^a  

^a UNIVERSITY OF MONASTIR   (Tunisia)

Author keywords

Carbapenem resistant Pseudomonas aeruginosa; Extended spectrum lactamases; Methicillin resistant Staphylococcus aureus; Multiresistance; Vancomycin resistant Enterococcus

Indexed keywords

BACTERIA (MICROORGANISMS); ENTEROBACTERIACEAE; ENTEROCOCCUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PSEUDOMONAS AERUGINOSA;

ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BIOLOGICAL MODEL; DRUG EFFECT; EUROPE; GENETICS; GEOGRAPHY; HISTORY; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOLECULAR EVOLUTION; PHYSIOLOGY; PREVALENCE; REVIEW;

ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, MICROBIAL; EUROPE; EVOLUTION, MOLECULAR; GEOGRAPHY; HISTORY, MEDIEVAL; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MODELS, BIOLOGICAL; PREVALENCE;

EID: 82255173922     PISSN: 00033898     EISSN: 19506112     Source Type: Journal    
DOI: 10.1684/abc.2011.0632     Document Type: Article

References (59)

1. Hawkey PM. The growing burden of antimicrobial resistance. J Antimicrob Chemother 2008 ; 62 : i1-9.
2. Livermore DM. Has the era of untreatable infections arrived? J Antimicrob Chemother 2009 ; 64 : i29-36.
3. Guilfoile PG. What are antibiotics? In : Antibiotic resistant bacteria. New York : ed. Chelsea House, 2007 : 10-21.
4. Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 2010 ; 74 : 417-33.
5. Wright GD. Antibiotic resistance in the environment: a link to the clinic? Curr Opin Microbiol 2010 ; 13 : 589-94.
6. Schjørring S, Krogfelt KA. Assessment of bacterial antibiotic resistance transfer in the gut. Int J Microbiol 2011 : sous presse.
7. Mulvey MR, Simor AE. Antimicrobial resistance in hospitals: how concerned should we be? CMAJ 2009 ; 180 : 408-15.
8. Guilfoile PG. The future of antibiotic resistance. In : Antibiotic resistant bacteria. New York : Chelsea House, 2007 : 93-9.
9. Woodford N, Livermore DM. Infections caused by Gram-positive bacteria: a review of the global challenge. J Infect 2009 ; 59(Suppl. 1) : S4-16.
10. Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis 2007 ; 13 : 1840-6. (Pubitemid 350248484)
11. Borg MA, de Kraker M, Scicluna E, van de Sande-Bruinsma N, Tiemersma E, Monen J, et al. Prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in invasive isolates from southern and eastern Mediterranean countries. J Antimicrob Chemother 2007 ; 60 : 1310-5. (Pubitemid 350168328)
12. Bordon J, Master RN, Clark RB, Duvvuri P, Karlowsky JA, Ayesu K, et al. Methicillin-resistant Staphylococcus aureus resistance to nonbeta-lactam antimicrobials in the United States from 1996 to 2008. Diagn Microbiol Infect Dis 2010 ; 67 : 395-8.
13. Draghi DC, Sheehan DJ, Hogan P, Sahm DF. In vitro activity of linezolid against key Gram-positive organisms isolated in the United States: results of the LEADER 2004 surveillance program. Antimicrob Agents Chemother 2005 ; 49 : 5024-32. (Pubitemid 41778916)
14. Jones RN, Ross JE, Castanheira M, Mendes RE. United-States resistance surveillance results for linezolid (LEADER Program for 2007). Diagn Microbiol Infect Dis 2008 ; 62 : 416-26.
15. Top J, Willems R, Bonten M. Emergence of CC17 Enterococcus faecium: from commensal to hospital-adapted pathogen.FEMSImmunol Med Microbiol 2008 ; 52 : 297-308. (Pubitemid 351420752)
16. Willems RJ, Top J, van Santen M, Robinson DA, Coque TM, et al. Global spread of vancomycin-resistant Enterococcus faecium from distinct nosocomial genetic complex. Emerg Infect Dis 2005 ; 11 : 821-8. (Pubitemid 40720841)
17. Paterson DL,BonomoRA. Extended spectrum ß-lactamases: a clinical update. Clin Microbiol Rev 2005 ; 18 : 657-86. (Pubitemid 41504510)
18. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBLproducing Enterobacteriaceae in Europe. Euro Surveill 2008 ; 13 : 573-83.
19. Hawser SP, Bouchillon SK, Hoban DJ, Badal RE. In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005-2007: results from the SMART study. Int J Antimicrob Agents 2009 ; 34 : 585-8.
20. Turner PJ. MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates. Diagn Microbiol Infect Dis 2009 ; 63 : 217-22.
21. Jones CH, Tuckman M, Keeney D, Ruzin A, Bradford PA. Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials. Antimicrob Agents Chemother 2009 ; 53 : 465-75.
22. Nicolas-Chanoine MH, Jarlier V. La collégiale de bactériologievirologie-hygiène hospitalière de l'Assistance Publique, hôpitaux de Paris, France. Extended-spectrum beta-lactamases in long-term-care facilities. Clin Microbiol Infect 2008 ; 14 : 111-6.
23. Romero L, López L, Rodríguez-Bãno J, Ramón Hernández J, Martínez-Martínez L, Pascual A. Long-term study of the frequency of Escherichia coli and Klebsiella pneumoniae isolates producing extendedspectrum ß-lactamases. Clin Microbiol Infect 2005 ; 11 : 625-31. (Pubitemid 41051378)
24. Moland ES, Hanson ND, Black JA, Hossain A, Song W, Thomson KS. Prevalence of newer beta-lactamases in gram-negative clinical isolates collected in the United States from 2001 to 2002. J Clin Microbiol 2006 ; 44 : 3318-24. (Pubitemid 44413771)
25. Castanheira M, Mendes RE, Rhomberg PR, Jones RN. Rapid emergence of blaCTX-M among Enterobacteriaceae in U.S. Medical Centers: molecular evaluation from the MYSTIC Program (2007). Microb Drug Resist 2008 ; 14 : 211-6.
26. Zhanel GG, Decorby M, Nichol KA, Baudry PJ, Karlowsky JA, Lagace-Wiens PR, et al. Characterization of methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci and extendedspectrum beta-lactamase-producing Escherichia coli in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study (2005-2006). Can J Infect Dis Med Microbiol 2008 ; 19 : 243-9.
27. Baudry PJ, Mccracken M, Lagace-Weins P, Mulvey MR, Zhanel GG, Hoban DJ, et al. Extended spectrum ß-lactamases producing Enterobacteriacae (ESBL-ENT) from patients in Canadian hospitals: CANWARD 2007 & 2008. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco : 12-15 September 2009 : C2-672.
28. Borg MA, Van de Sande-Bruinsma N, Scicluna E, De Kraker M, Tiemersma E, Monen J, et al. Antimicrobial resistance in invasive strains of Escherichia coli from southern and eastern Mediterranean laboratories. Clin Microbiol Infect 2008 ; 14 : 789-96.
29. Gray KJ, Wilson LK, Phiri A, Corkill JE, French N, Hart CA. Identification and characterization of ceftriaxone resistance and extendedspectrum beta-lactamases in Malawian bacteraemic Enterobacteriaceae. J Antimicrob Chemother 2006 ; 57 : 661-5.
30. Bouchillon SK, Johnson BM, Hoban DJ, Johnson JL, Dowzicky MJ, Wu DH, et al. Determining incidence of extended spectrum beta-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001-2002. Int J Antimicrob Agents 2004 ; 24 : 119-24. (Pubitemid 38993689)
31. Pitout JD. Infections with extended-spectrum beta-lactamaseproducing Enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs 2010 ; 70 : 313-33.
32. Canton R, Coque TM. The CTX-M beta-lactamase pandemic. Curr Opin Microbiol 2006 ; 9 : 466-75.
33. Hawkey PM, Jones AM. The changing epidemiology of resistance. J Antimicrob Chemother 2009 ; 64 : i3-10.
34. Elhani D, Bakir L, Aouni M, Passet V, Arlet G, Brisse S, et al. Molecular epidemiology of extended-spectrum ß-lactamase-producing Klebsiella pneumoniae strains in a university hospital in Tunis, Tunisia, 1999-2005. Clin Microbiol Infect 2010 ; 16 : 157-64.
35. Poirel L, Naas T, Nordmann P. Genetic support of extended-spectrum ß-lactamases. Clin Microbiol Infect 2008 ; 14(Suppl. 1) : 75-81.
36. Hawkey PM. Molecular epidemiology of clinically significant antibiotic resistance genes. Br J Pharmacol 2008 ; 153(Suppl. 1) : S406-13. (Pubitemid 351341006)
37. Bortolaia V, Guardabassi L, Bisgaard M, Larsen J, Bojesen AM. Escherichia coli producing CTX-M-1, -2, and -9 group beta-lactamases in organic chicken egg production. Antimicrob Agents Chemother 2010 ; 54 : 3527-8.
38. Cortés P, Blanc V, Mora A, Dahbi G, Blanco JE, Blanco M, et al. Isolation and characterization of potentially pathogenic antimicrobial-resistant Escherichia coli strains from chicken and pig farms in Spain. Appl Environ Microbiol 2010 ; 76 : 2799-805.
39. Simões RR, Poirel L, Da Costa PM, Nordmann P. Seagulls and beaches as reservoirs for multidrug-resistant Escherichia coli. Emerg Infect Dis 2010 ; 16 : 110-2.
40. Ewers C, Grobbel M, Stamm I, Kopp PA, Diehl I, Semmler T, et al. Emergence of human pandemic O25:H4-ST131 CTX-M-15 extendedspectrum-beta- lactamase-producing Escherichia coli among companion animals. J Antimicrob Chemother 2010 ; 65 : 651-60.
41. Floret N, Bertrand X, Thouverez M, Talon D. Infections nosocomiales à Pseudomonas aeruginosa : origine exogène ou endogène de la bactérie responsable ? Pathol Biol (Paris) 2009 ; 57 : 9-12.
42. Barbier F, Wolff M. Multirésistance chez Pseudomonas aeruginosa vers l'impasse thérapeutique ? Med Sci (Paris) 2010 ; 26 : 960-8.
43. Nordmann P. Résistance aux carbapénèmes chez les bacilles à Gram négatif. Med Sci (Paris) 2010 ; 26 : 950-9.
44. Rhomberg PR, Jones RN. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008). Diagn Microbiol Infect Dis 2009 ; 65 : 414-26.
45. Walsh TR. Clinically significant carbapenemases: an update. Curr Opin Infect Dis 2008 ; 21 : 367-71.
46. Tsakris A, Poulou A, Kristo I, Pittaras T, Spanakis N, Pournaras S, et al. Large dissemination of VIM-2-metallo-{beta}-lactamaseproducing Pseudomonas aeruginosa strains causing health careassociated community-onset infections. J Clin Microbiol 2009 ; 47 : 3524-9.
47. Samuelsen O, Toleman MA, Sundsfjord A, Rydberg J, Leegaard TM,Walder M, et al. Molecular epidemiology of metallo-beta-lactamaseproducing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. Antimicrob Agents Chemother 2010 ; 54 : 346-52.
48. Juan C, Zamorano L, Mena A, Albertí S, Pérez JL, Oliver A. Metallobeta-lactamase-producing Pseudomonas putida as a reservoir of multidrug resistance elements that can be transferred to successful Pseudomonas aeruginosa clones. J Antimicrob Chemother 2010 ; 65 : 474-8.
49. Giske CG, Libisch B, Colinon C, Scoulica E, Pagani L, Füzi M, et al. Establishing clonal relationships between VIM-1-like metallobeta-lactamase- producing Pseudomonas aeruginosa strains from four European countries by multilocus sequence typing. J Clin Microbiol 2006 ; 44 : 4309-15. (Pubitemid 44937057)
50. Jovcic B, Vasiljevic Z, Djukic S, Topisirovic L, Kojic M. Emergence of VIM-2 metallo-{beta}-lactamase-producing Pseudomonas aeruginosa isolates in a paediatric hospital in Serbia. J Med Microbiol 2011 ; 60 : 868-9.
51. Khosravi Y, Tay ST, Vadivelu J. Analysis of integrons and associated gene cassettes of MBL positive Pseudomonas aeruginosa in Malaysia. J Med Microbiol 2011 ; 60 : 988-94.
52. Van der Bij AK, Van Mansfeld R, Peirano G, Goessens WH, Severin JA, Pitout JD, et al. First outbreak of VIM-2 metallo-ß-lactamase-producing Pseudomonas aeruginosa in The Netherlands: microbiology, epidemiology and clinical outcomes. Int J Antimicrob Agents 2011 ; 37 : 513-8.
53. Ktari S, Mnif B, Znazen A, Rekik M, Mezghani S, Mahjoubi-Rhimi F, et al. Diversity of ß-lactamases in Pseudomonas aeruginosa isolates producing metallo-ß-lactamase in two Tunisian hospitals. Microb Drug Resist 2011 ; 17 : 25-30.
54. Hocquet D, Plésiat P, Dehecq B, Mariotte P, Talon D, Bertrand X, et al. Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. Antimicrob Agents Chemother 2010 ; 54 : 3512-5.
55. Elias J, Schoen C, Heinze G, Valenza G, Gerharz E, Gerharz H, et al. Nosocomial outbreak of VIM-2 metallo-ß-lactamase-producing Pseudomonas aeruginosa associated with retrograde urography. Clin Microbiol Infect 2010 ; 16 : 1494-500.
56. Bosnjak Z, BedenícB, Mazzariol A, Jarza-Davila N, Suto S, KalenícS. VIM-2 beta-lactamase in Pseudomonas aeruginosa isolates from Zagreb, Croatia. Scand J Infect Dis 2010 ; 42 : 193-7.
57. Duljasz W, Gniadkowski M, Sitter S, Wojna A, Jebelean C. First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria. Antimicrob Agents Chemother 2009 ; 53 : 2221-2.
58. Empel J, Filczak K, Mrówka A, Hryniewicz W, Livermore DM, Gniadkowski M. Outbreak of Pseudomonas aeruginosa infections with PER-1 extended-spectrum beta-lactamase in Warsaw, Poland: further evidence for an international clonal complex. J Clin Microbiol 2007 ; 45 : 2829-34. (Pubitemid 47417322)
59. Kouda S, Ohara M, Onodera M, Fujiue Y, Sasaki M, Kohara T, et al. Increased prevalence and clonal dissemination of multidrug-resistant Pseudomonas aeruginosa with the bla IMP-1 gene cassette in Hiroshima. J Antimicrob Chemother 2009 ; 64 : 46-51.